The patent provides the company with exclusive rights to LOR-253 until 2026.
The patent covers LOR-253 composition of matter and its use in the treatment of a wide range of cancers, including non-small cell lung, colon, breast, and prostate tumors, as well as melanoma and leukemia.
LOR-253 is in a Phase I study in patients with advanced or metastatic solid tumors who are unresponsive to conventional therapy or for which no effective therapy is available.
Lorus president and CEO Aiping Young said the new patent gives long-term protection for LOR-253 in Canada, and the company considers it to be a valuable asset in expanding IP portfolio for the novel cancer therapy.